- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00599222
The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study
November 21, 2011 updated by: Anders Kvanta
A Prospective, Randomized, Controlled Study on Intravitreal Ranibizumab (Lucentis) Combined With Transpupillary Thermotherapy (TTT) for Neovascular Age-related Macular Degeneration (AMD)
Neovascular age-related macular degeneration (AMD) is the leading cause of severe vision loss in the Western world.
Intravitreal ranibizumab has recently become the treatment of choice for neovascular (AMD).
Limitations to ranibizumab however include the high cost for the drug and the need for frequent intravitreal re-injections.
The investigators' hypothesis is that when ranibizumab is combined with transpupillary thermotherapy (TTT) the number of necessary retreatments with Lucentis will be significantly reduced as compared to ranibizumab alone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Neovascular age-related macular degeneration (AMD) is caused by an ingrowth of pathological vessels under the macula.
Experimental studies have demonstrated that vascular endothelial growth factor (VEGF) is centrally involved in this process.
For this reason, anti-VEGF drugs, in particular ranibizumab, as become the treatment of choice for neovascular AMD.
Ranibizumab use is limited by its high cost.
Also, ranibizumab requires repeated (sometimes up to monthly) intravitreal injections for many years.
Strategies to reduce the burden of this treatment on the patient as well as on the health care system will be critical.
Combination therapy is an attractive such possibility.
Transpupillary thermotherapy (TTT) is a technique by which vascular occlusion can be induced by delivering radiation at near infrared intensity to the target tissue through the pupil.
Several reports have indicated that TTT may be used to slow disease progression in patients with neovascular AMD.
In this study we examine whether combined ranibizumab and TTT will reduce the number of ranibizumab injections compared with ranibizumab alone (sham TTT).
The study will go on for 2 years with an interim report after 1 year.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden, 11282
- St Eriks Eye Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with subfoveal neovascular AMD with either classic/predominantly classic or occult lesions
- visual acuity => 20/200
Exclusion Criteria:
- subretinal fibrosis or atrophy under the fovea
- patients previously treated for neovascular AMD in the study eye
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: TTT
TTT is given every three months
|
0.5 mg intravitreal injection
Other Names:
Transpupillary thermotherapy (TTT)
|
SHAM_COMPARATOR: Sham TTT
Sham TTT is given every three months
|
0.5 mg intravitreal injection
Other Names:
Sham Transpupillary thermotherapy (TTT)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients that will need 5 injections (loading phase excluded) or less with ranibizumab
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients losing less than 15 letters on the ETDRS visual acuity chart
Time Frame: 1 year
|
1 year
|
Proportion of patients gaining more than 15 letters on the ETDRS visual acuity chart
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anders Kvanta, St Eriks Eye Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (ACTUAL)
November 1, 2009
Study Completion (ACTUAL)
February 1, 2010
Study Registration Dates
First Submitted
January 10, 2008
First Submitted That Met QC Criteria
January 10, 2008
First Posted (ESTIMATE)
January 23, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
November 22, 2011
Last Update Submitted That Met QC Criteria
November 21, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LUTA001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted